argenx SE (ARGX)
undefined
undefined%
At close: undefined
607.21
0.09%
After-hours Dec 13, 2024, 04:56 PM EST

Company Description

argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France.

Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, and chronic inflammatory demyelinating polyneuropathy in Phase III clinical trials; bullous pemphigoid and idiopathic inflammatory myopathy in Phase II/III clinical trials; and ENHANZE SC in Pre-clinical study.

The company is also developing immunology innovation programs, including cusatuzumab for hematological cancer, as well as high risk MDS; ARGX-119, an antibody that targets muscle-specific tyrosine kinase stage; ARGX-117 for severe autoimmune indications; ARGX-118 for airway inflammation; and ARGX-120 to treat autoimmune diseases.

In addition, its partnered product candidates include ARGX-115 for the treatment of cancer; ARGX-112 to treat interleukin-22 receptor; and ARGX-114, an antibody directed against the MET receptor.

The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., University of Texas, BioWa, Inc., Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.

argenx SE
argenx SE logo
Country NL
IPO Date May 18, 2017
Industry Biotechnology
Sector Healthcare
Employees 1,148
CEO Timothy Van Hauwermeiren EMBA, M.Sc.

Contact Details

Address:
Willemstraat 5
Breda,
NL
Website https://www.argenx.com

Stock Details

Ticker Symbol ARGX
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001697862
CUSIP Number 04016X101
ISIN Number NL0010832176
Employer ID 00-0000000
SIC Code 2836

Key Executives

Name Position
Timothy Van Hauwermeiren EMBA, M.Sc. Chief Executive Officer & Executive Director
Karen Massey Chief Operating Officer
Karl Gubitz Chief Financial Officer
Andria Wilk Global Head of Quality
Arjen Lemmen M.Sc. Vice President of Corporate Development & Strategy
Beth DelGiacco Vice President and Global Head of Corporate Communications & Investor Relations
Filip Borgions Vice President & Global Head of Technical Operations
Malini Moorthy General Counsel
Marc Schorpion Global Head of Human Resources
Peter Ulrichts Chief Scientific Officer

Latest SEC Filings

Date Type Title
Nov 20, 2024 6-K Filing
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial own...
Nov 12, 2024 6-K Filing
Oct 31, 2024 6-K Filing
Oct 15, 2024 6-K Filing
Sep 19, 2024 6-K Filing
Jul 25, 2024 6-K Filing
Jul 16, 2024 6-K Filing
Jul 16, 2024 6-K Filing